drugset / Trial / NCT00203905
A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is to evaluate time to progression in eligible patients with cancer of the oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus when treated with the concomitant chemoradiotherapy regimen of bevacizumab/5-fluorouracil (5-FU)/hydroxyurea/radiation therapy (B-FHX) in comparison to 5-fluorouracil hydroxyurea (FHX) alone.
Timeline
- Start
- 2004-01
- Primary completion
- 2007-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Background | Hydroxyurea | Other / unclassified | 500 mg | Oral |
| Background | fluorouracil | Small molecule | 600 mg/m2 | — |